Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Brain Neoplasms × Ipilimumab × Clear all

Status

Sponsor Class

Study Type

Interventional 19 Observational 1

Sponsor

Cancer Type

Conditions

Melanoma 11 Neoplasms 4 Lung Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Urinary Bladder Neoplasms 1 Recurrent Squamous Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Motor Activity 1 Kidney Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1 Adenocarcinoma 1

Interventions

Surveys and Questionnaires 14 Radiosurgery 12 Magnetic Resonance Imaging 11 Magnetic Resonance Spectroscopy 10 Neuropsychological Tests 8 Radiotherapy 6 Radiation 4 Blood Specimen Collection 4 Surgical Procedures, Operative 2 Physical Examination 2 Phlebotomy 2 Perfusion Magnetic Resonance Imaging 2 Patient Reported Outcome Measures 2 Lead 2 Interviews as Topic 2 Bevacizumab 2 Amplified Fragment Length Polymorphism Analysis 2 Aminolevulinic Acid 2 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pembrolizumab 1 lorlatinib 1 gadoterate meglumine 1 gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate 1 gadobenic acid 1 fluciclovine F-18 1 Wechsler Scales 1 Watchful Waiting 1 Ultrasonography 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03458455 2023-11-01

TREATMENT

Oslo University Hospital

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡